Mediwound (NASDAQ:MDWD) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.


This table compares Mediwound and Tilray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mediwound -783.30% -210.90% -33.92%
Tilray N/A N/A N/A

Analyst Recommendations

This is a breakdown of current ratings for Mediwound and Tilray, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mediwound 0 0 5 0 3.00
Tilray 0 2 1 0 2.33

Mediwound currently has a consensus target price of $10.60, suggesting a potential upside of 64.34%. Tilray has a consensus target price of $34.50, suggesting a potential downside of 65.33%. Given Mediwound’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Mediwound is more favorable than Tilray.

Insider & Institutional Ownership

32.1% of Mediwound shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Mediwound and Tilray’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mediwound $2.50 million 69.79 -$22.14 million ($0.62) -10.40
Tilray N/A N/A N/A N/A N/A

Tilray has lower revenue, but higher earnings than Mediwound.


Mediwound beats Tilray on 5 of the 8 factors compared between the two stocks.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Tilray Company Profile

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with's FREE daily email newsletter.